Combination of Pertuzumab and Erlotinib as 2nd-/3rd-Line (2/3L) Treatment for Patients (pts) With Metastatic Non-Small Cell Lung Cancer (NSCLC) - Safety and Anti-Tumour Activity by FDG-PET/CT Imaging Changes

被引：0
|
作者：
Hughes, B. [1 ]
Mileshkin, L. [2 ]
Townley, P. [3 ]
Gitlitz, B. [4 ]
Eaton, K. [5 ]
Mitchell, P. [6 ]
Hicks, R. [2 ]
Loecke, D. [7 ]
Amler, L. [7 ]
Pirzkall, A. [7 ]
机构：
[1] Royal Brisbane & Womens Hosp, Canc Care Serv, Brisbane, Qld, Australia
[2] Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Melbourne, Vic, Australia
[3] Nebraska Canc Specialists, Methodist Estabrook Canc Ctr, Omaha, NE USA
[4] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Univ Washington, Med Ctr, Dept Internal Med, Seattle, WA 98195 USA
[6] Austin Hosp, Ludwig Med Oncol Dept, Melbourne, Vic 3084, Australia
[7] Genentech Inc, BioOncol, San Francisco, CA 94080 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72431-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S629 / S629
页数：1
相关论文
共 50 条
  • [21] Clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in patients (pts) with checkpoint inhibitor (CPI) -pretreated advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a P2 trial
    Larson, Timothy
    Jotte, Robert M.
    Abdelaziz, Ahmed Mohammed Fouad
    Konduri, Kartik
    Richards, Donald A.
    Meshad, Michael W.
    Nagaiah, Govardhanan
    Spira, Alexander I.
    Khandelwal, Pankaj
    Lorber, Ilana
    Kedem, Tal Hetzroni
    Rozencweig, Marcel
    Fields, Scott Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Gene copy numbers of signaling components downstream of EGFR identify non small cell lung cancer (NSCLC) patients with poor outcomes on 2nd/3rd line gefitinib therapy
    Morrison, Larry E.
    Basu, Sanjib
    Buckingham, Lela E.
    Kaiser, Kelly A.
    Fidler, Mary J.
    Batus, Marta
    Jacobson, Kris K.
    Jewell, Susan S.
    Coon, John S.
    Bonomi, Philip D.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S350 - S351
  • [23] TIGER 1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686) or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC).
    Camidge, D. Ross
    Wolf, Juergen
    Litten, Jason B.
    Higashi, Linda A.
    Isaacson, Jeffrey D.
    Mok, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Second-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first-line (1L) immuno-oncology (IO) monotherapy (mono tx)
    Talbot, D.
    Fish, S. M.
    Ong, T. Jin
    Flick, E. D.
    Waterhouse, D. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870 long-term results
    Lu, S.
    Cheng, Y.
    Zhou, J.
    Wang, M.
    Zhao, J.
    Wang, B.
    Chen, G.
    Feng, J.
    Ma, Z.
    Wu, L.
    Wang, C.
    Ma, K.
    Zhang, S.
    Liang, J.
    Song, Y.
    Wang, J.
    Wu, Y-L.
    Li, A.
    Huang, Y.
    Chang, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S35 - S36
  • [26] Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer
    Shimizu, Toshio
    Yonesaka, Kimio
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Haratani, Koji
    Yamada, Hironori
    Ohwada, Shoichi
    Kamiyama, Emi
    Nakagawa, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 489 - 495
  • [27] Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer
    Toshio Shimizu
    Kimio Yonesaka
    Hidetoshi Hayashi
    Tsutomu Iwasa
    Koji Haratani
    Hironori Yamada
    Shoichi Ohwada
    Emi Kamiyama
    Kazuhiko Nakagawa
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 489 - 495
  • [28] Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) -results from ASCEND-2 and ASCEND-3
    Park, K.
    Tan, D.
    Ahn, M. -J.
    Yu, C. -J.
    Tsai, C. -M.
    Hida, T.
    Nishio, M.
    Branle, F.
    Emeremni, C.
    Mok, T.
    ANNALS OF ONCOLOGY, 2015, 26 : 126 - 127
  • [29] The role of FDG-PET before and 3 weeks after neoadjuant chemoradiotherapy (NACRT) in predicting N2 clearing and survival after surgical resection in patients with biopsy-proven N2 positive non-small cell lung carcinoma (NSCLC)
    Jang, G.
    Kim, S.
    Ryu, J.
    Moon, D.
    Sohn, H.
    Lee, D.
    Suh, C.
    Lee, J.
    Choi, E.
    Park, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] SAFETY, PHARMACOKINETICS, AND EFFICACY OF RECOMBINANT HUMAN (RH)APO2L/TRAIL IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB (PCB) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): RESULTS OF A PHASE 1B STUDY
    Soria, J.
    Smit, E.
    Khayat, D.
    Besse, B.
    Burton, J.
    Yang, X.
    Hsu, M.
    Braun, A.
    Reese, D.
    Blackhall, F. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 153 - 153
12345